Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2Neoplasms 2Uterine Cervical Neoplasms 1Pregnancy Related 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Endometrial Neoplasms 1Burkitt Lymphoma 1

Interventions

Gemcitabine 54130-nm albumin-bound paclitaxel 29Magnetic Resonance Spectroscopy 21Taxes 18Fluorouracil 18Specimen Handling 17Oxaliplatin 17Leucovorin 17Drug Therapy 17Albumin-Bound Paclitaxel 17Irinotecan 14pembrolizumab 13Cyclophosphamide 11Blood Specimen Collection 11Biopsy 11fludarabine 10Radiosurgery 9irinotecan sucrosofate 8folfirinox 6Magnetic Resonance Imaging 6Cetuximab 6Bevacizumab 6dehydroftorafur 5Surveys and Questionnaires 5Nivolumab 5Endoscopic Ultrasound-Guided Fine Needle Aspiration 5sintilimab 4olaparib 4balstilimab 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Neoplasms × Antibodies, Monoclonal × Clear all
NCT05462496 2024-10-15

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡